160 related articles for article (PubMed ID: 35961380)
1. Risankizumab for Induction and Maintenance of Remission in Crohn's Disease.
Khanna R
Gastroenterology; 2022 Nov; 163(5):1470-1471. PubMed ID: 35961380
[No Abstract] [Full Text] [Related]
2. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
[TBL] [Abstract][Full Text] [Related]
3. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
5. In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk.
Oliver D; Talley NJ
Ann Intern Med; 2022 Oct; 175(10):JC114. PubMed ID: 36191314
[TBL] [Abstract][Full Text] [Related]
6. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes.
Horst S; Cross RK
Drug Des Devel Ther; 2023; 17():273-282. PubMed ID: 36747585
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
[TBL] [Abstract][Full Text] [Related]
8. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
Visvanathan S; Baum P; Salas A; Vinisko R; Schmid R; Grebe KM; Davis JW; Wallace K; Böcher WO; Padula SJ; Fine JS; Panés J
J Crohns Colitis; 2018 Nov; 12(10):1170-1179. PubMed ID: 30032288
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
Behm BW; Bickston SJ
Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
[TBL] [Abstract][Full Text] [Related]
11. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of concomitant Crohn's disease and psoriasis with risankizumab.
Tursi A; Florio T; Tiano M
Eur J Gastroenterol Hepatol; 2021 Nov; 33(11):1462-1464. PubMed ID: 34597287
[No Abstract] [Full Text] [Related]
15. [A Case of Crohn's Disease Showing Favorable Response to Induction and Maintenance Therapy with Methotrexate after Failure of Anti-tumor Necrosis Factor Therapy].
Choi JR; Yun GW; Park YM; Kim JH; Youn YH; Park HJ; Park JJ
Korean J Gastroenterol; 2015 Oct; 66(4):231-6. PubMed ID: 26493510
[TBL] [Abstract][Full Text] [Related]
16. Maintenance infliximab for Crohn's disease.
Cottone M; Orlando A; Casà A; Oliva L
Lancet; 2002 Nov; 360(9345):1602; author reply 1602-3. PubMed ID: 12443622
[No Abstract] [Full Text] [Related]
17. How deep is remission in perianal Crohn's disease and do imaging modalities matter?
Savoye G; Savoye-Collet C
Am J Gastroenterol; 2010 Jun; 105(6):1445-6; author reply 1446. PubMed ID: 20523317
[No Abstract] [Full Text] [Related]
18. Adalimumab induction for Crohn's disease.
Cottone M; Mocciaro F; Scimeca D
Gastroenterology; 2006 May; 130(6):1929. PubMed ID: 16697762
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
[TBL] [Abstract][Full Text] [Related]
20. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
